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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: There are few studies on heparin-induced thrombocytopenia (HIT)
reported from Taiwan and Asian countries. We conducted a prospective study to investigate
the frequency of HIT in patients undergoing cardiopulmonary bypass surgeries.
Methods: A cohort of 54 patients was enrolled from January 01, 2010 to October 31, 2011. Pa-
tients’ clinical information was obtained for 4T score classification. Plasma (2e4 mL) was also
collected before surgery and on Days 5 and 10 following heparin administration during the
bypass procedure. This was tested for anti-heparin/PF4 antibodies and functional assay using
flow cytometry (FC).
Results: The mean platelet count for this cohort followed the expected pattern in the postop-
erative setting. Seven of the 54 (13%) patients had positive antibodies assays before bypass sur-
gery. This increased to 32% on Day 5 and was markedly elevated to 63% on Day 10 after surgery.
Only one of the 54 patients (1.8%) was found to have both positive antibody assay and platelet
activation, but no clinical HIT/thrombosis developed.
Conclusion: Our study is the first report on the rates of HIT in the setting of cardiopulmonary
bypass surgery in Taiwan and demonstrated no clinical HIT occurrence, despite the high fre-
quency of HIT antibody in our cohort.
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01, 2010 to October 31, 2011. This study was approved byHeparin-induced thrombocytopenia (HIT) is an acquired
immunologic and thrombotic disorder characterized by
thrombocytopenia with/without arterial or venous throm-
bosis following heparin exposure. Devastating complica-
tions such as limb gangrene and even fatality may occur if it
is not recognized and treated in a timely fashion.1 Early
identification of HIT is therefore essential for the appro-
priate clinical management of affected patients. In the
typical presentation of HIT, thrombocytopenia with or
without vascular thrombosis usually develops on Days 5e12
after heparin exposure.2 The reported incidence of HIT is
1e5%, depending on the clinical situation and the type of
heparin used.3
Patients undergoing cardiovascular or orthopedic sur-
geries have a higher probability of developing HIT anti-
bodies as compared to medical patients exposed to
heparin.4,5 However, many patients with detectable anti-
heparin/PF4 antibodies may not develop clinical HIT. In
fact, only 5e50% of these patients will develop HIT,
depending on the patient population.6 The relationship
between the clinical presentation of HIT, the presence of
HIT antibodies, and the type of assay used can be concep-
tualized as an iceberg model, as proposed by Warkentin.7
HIT has been well recognized in Western countries, but
there are few studies reported from Taiwan and other Asian
countries and the Taiwanese have been considered ethni-
cally as a low-risk population for developing thrombosis.8
Our colleagues have previously reported a female patient
with breast cancer who developed progressive thrombocy-
topenia and venous thrombosis of axillary vessels with
impending digit and limb gangrene after Port-A catheter
insertion with minimal heparin exposure.9 She was diag-
nosed as having HIT by positive enzyme-linked immuno-
sorbent assay (ELISA), and was successfully treated with
heparin cessation and subsequent thrombolytic therapy.
Systematic studies of the frequency of HIT in various sub-
sets of patients in Taiwan have so far been lacking.
Therefore, we consider HIT to be a disease needing further
exploration in the Taiwanese population to better under-
stand the epidemiologic and clinical spectrum.
In this study, we focus on patients undergoing cardio-
pulmonary bypass surgery with unfractionated heparin
(UFH) exposure, because these patients have been identi-
fied as having a high risk of developing HIT antibodies. The
aims of this study were: (1) to determine the frequency of
anti-heparin/platelet factor 4 antibody formation in
Taiwanese patients undergoing cardiopulmonary bypass
surgeries; (2) to estimate how many of these patients have
a positive functional assay for HIT antibodies; and (3) to
determine the overall frequency of clinical HITT in this
cohort of patients.Patients and methods
Patients
We conducted a prospective study involving a cohort of
patients who had undergone cardiac surgeries with UFH usefor cardiopulmonary bypass at our institution from January
our institutional review board and signed informed consent
was obtained from each patient before their enrollment.
Each patient’s medical history including age, sex, disease
and type of operation were recorded. Additionally, a series
of platelet counts before surgery and Days 0, 2, 5, 8, and 10
after surgery were collected for analysis.
None of the 54 patients in this cohort was given either
UFH or low molecular weight heparin for deep venous
thrombosis (DVT)/pulmonary embolism (PE) prophylaxis in
the intensive care unit after surgery.
Inclusion criteria
Patients who were given UFH for extracorporeal anti-
coagulation while undergoing cardiopulmonary bypass sur-
gery were included.
Exclusion criteria
Patients with known thrombocytopenia (platelet
count< 100 103/mm3) from causes such as infection,
sepsis, liver disease, or acute disseminated intravascular
coagulopathy before cardiac surgery were excluded.
Heparin use
UFH (Agglutex, China Chemical and Pharmaceutical Cor-
poration, Taipei, Taiwan), a porcine heparin sodium, was
given by intravenous bolus of 300 units/kg with additional
dosing to get activated clotting time >400 seconds before
cardiopulmonary bypass surgery, followed by repeated UFH
boluses as needed to keep the activated clotting time >400
seconds continually during cardiopulmonary bypass.
Platelet transfusion
One unit of platelet pheresis product was transfused for
each patient after surgery, which is a standard practice for
patients who receive cardiac surgery at our institution.
Patient’s plasma
Each patient’s plasma (2e4 mL) was collected in a vacuum
tube containing 3.2% sodium citrate as an anticoagulant
before surgery and on Days 5 and 10 after heparin admin-
istration. The samples were centrifuged, aliquoted, and
stored at 80C. One stored frozen sample from each pa-
tient was thawed to test for anti-heparin/PF4 antibodies by
ELISA. If the result of the ELISA was positive, the other one
was thawed and subjected to functional assay using the
flow cytometry (FC) method.Methods
ELISA testing for detection of HIT antibodies
ELISA (Asserachrom HPIA, Stago, Asnie`res, France) was used
according to the manufacturer’s guidelines. This assay
determined the amount of antibodies (IgG, IgM, and IgA)
against heparin-PF4 complexes in a patient’s plasma. The
absorbance value of each tested sample was measured at
450 nm. The HIT ELISA assay was classified as positive if the
absorbance value, optical density (OD), of the tested
sample was greater than the absorbance value of the
reference reagent multiplied by a fraction number (0.27 or
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the manufacturer’s recommendations.
FC assay for detection of HIT antibodies
The FC assay was performed as reported by Tomer,10 with
some modifications as follows: (1) the use of normal
donor platelets regardless of blood group type; (2) the
use of CD61 (glycoprotein IIIa) and CD62p (p-selectin) as
markers of platelet identification and activation,
respectively; (3) the use of adenosine diphosphate to
confirm normal platelet activation; (4) all procedures
were performed at room temperature (20e25 C); (5) use
of phosphate-buffered saline as the buffer solution for
the entire procedure; and (6) analysis of 10,000 platelets
per sample.
The plasma of patients whose ELISA was positive was
subjected to the FC assay to assess platelet activation. The
patient’s plasma was incubated with no heparin, 0.1 IU/mL,
0.3 IU/mL, and 100 IU/mL UFH. The samples without UFH
and those with 100 IU/mL heparin were used as internal
negative controls. The definition of a positive FC assay was
adopted from two previous studies.11,12 The proportion of
activated platelets was at least >11% in the presence of
heparin (0.1 or 0.3 IU/mL) compared with baseline (no
heparin) and the activation could be suppressed by a high
dose of heparin (100 IU/mL) evidenced by a ratio of more
than two between platelet activation percentage at 0.3 and
100 IU/mL heparin.
Clinical HIT
A diagnosis of clinical HIT was established if the following
three criteria were fulfilled: (1) intermediate or high
probability group by Warkentin pretest scoring system (4T
scores).13 In brief, the 4Ts refer to four items including
thrombocytopenia, time to platelet count decrease,
thrombosis, and the presence of other causes for throm-
bocytopenia. Each item has 0e2 points and the total score
from these four items is used to classify patients into three
probability categories: highZ 6e8, intermediateZ 4e5,
and lowZ 0e3; (2) positive ELISA assay; and (3) positive
functional assay of platelet activation.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
for Windows, version 5.01 (La Jolla, CA, USA). The inde-
pendent t test was used for calculation and comparison of
the continuous data including patients’ series of average
platelet count and the absorbance values (OD unit) of anti-
heparin/PF4 antibodies titer before and on Days 5 and 10
after UFH exposure assayed by ELISA. A p value< 0.05 was
considered statistically significant.Table 1 Clinical information on 54 patients undergoing cardiop
Disease Total no.
of patients
Sex
(M/F)
Age, med
(range)
Coronary artery disease 31 23/8 71 (44e93
Valvular heart disease 19 8/11 76 (52e86
Miscellaneous 4 2/2 59 (38e75Results
There were 54 consecutive patients who had clinical evalu-
ation with a full history and physical, and a series of platelet
counts and plasma samples for analysis before and after
cardiopulmonary bypass surgery and on Days 5 and 10
thereafter. There were 34 male and 20 female patients
enrolled in this study and their median age was 72 years with
a range of 38e93 years. The demography, cardiac disease,
and types of surgery for this cohort of 54 patients are listed in
Table 1. The total dose of UFH ranged from 14,000 U to
33,000 U, with a median of 19,000 U. None of the patients
developed thromboembolic events postoperatively.
Platelet count trajectory
All but five patients were given one unit of pheresis
platelets after cardiopulmonary bypass surgery on the
operative day. Five patients did not receive platelet
transfusion because of low perioperative bleeding or un-
availability of the platelet pheresis units. The change in
platelet count before and after operation with UFH expo-
sure is depicted in Fig. 1. The mean platelet count
decreased from 186.53 73.81 103/mL preoperatively, to
the lowest value of 106.62 38.75 103/mL on Day 2 after
surgery (p< 0.001). The mean platelet count then
increased up to 127.08 57.66 103/mL on Day 5 and
239.17 107.42 103/mL on Day 10 (p< 0.001 as compared
to that on Day 2).
The average platelet count was compared between pa-
tients with and without positive anti-heparin/PF4 anti-
bodies at various time points before and after surgery, as
shown in Fig. 2. Although those patients whose ELISA tests
were positive (36 patients) had higher mean platelet counts
compared to those with a negative ELISA test (18 patients)
at all six time points, there was no statistical difference in
the mean platelet count between these two groups.
The probability of clinical HIT
By the 4Ts classification, none of the 54 patients had a high
probability of HIT. There were 18 patients with an inter-
mediate probability, including two with five points and 16
with four points. The other 36 patients all had a low
probability.
Absorbance value of the ELISA assay
Seven of the 54 (13%) patients had positive anti-heparin/
PF4 antibodies before the cardiac surgery. The percentageulmonary bypass surgeries.
ian Surgery Duration of
cardiopulmonary
bypass (h)
) Coronary arterial bypass grafts 1e2
) Valves repair or replacement 1e2
) Septal myomectomy, removal
of a cardiac tumor, etc.
1
Figure 1 The change in perioperative platelet count. The
error bar represents mean standard deviation.
Figure 3 The change in the mean titer of positive anti-HIT
antibodies. The error bar represents mean standard
deviation.
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(17 patients) on Day 5 after surgery, and was markedly
elevated to 63% (34 patients) on Day 10 after surgery. The
average antibody titer expressed by OD value in patients
with positive anti-heparin/PF4 antibodies is shown in Fig. 3.
The OD value was 0.79 0.45 (mean standard deviation)
before surgery, which increased to the highest level of
1.70 1.08 on Day 5 after surgery (p< 0.05 as compared to
that before surgery). The OD value on Day 10 after surgery
was 1.64 0.99, which was not statistically different in
comparison to the absorbance value on Day 5.Platelet activation by FC assay
Only one patient, who had undergone mitral valve repair
and tricuspid valve annuloplasty, was found to have positive
platelet activation by the FC assay, as shown in Fig. 4. Anti-
heparin/PF4 antibodies were first detected by ELISA in this
65-year-old female patient on Day 10 after surgery, but
she had no clinical persistent thrombocytopenia or throm-
boembolic events. Her clinical HIT score was 2 according to
the Warkentin 4Ts scoring system, which classified herFigure 2 Comparison of the platelet count change over the
time from preoperation to Day 10 after surgery. The solid line
(upper) represents the platelet count in patients with anti-
heparin/PF4 antibodies and the dotted line (lower) repre-
sents the platelet count in patients without these antibodies.
There was no statistical difference in platelet counts at the
stated time points on preoperation (op), op(0), op(2), op(5),
op(8), and op(10) between the two groups of patients.probability as low risk; we therefore chose not to treat her
with a direct thrombin inhibitor. Thrombocytopenia and/or
thrombotic events were not experienced during 6 months of
follow up after surgery.Discussion
Over the past decade, HIT has been increasingly recognized
worldwide as a clinically important entity, with the po-
tential for serious and even fatal consequences if it is not
recognized and treated appropriately. This awareness has
been lacking in Taiwan outside the setting of large aca-
demic referral centers, largely due to a perception that the
incidence is very low. The absence of studies defining the
true incidence has further hindered educational efforts and
needs to be addressed. Our study represents the first step
in that direction and looks at a specific subset of patients
exposed to heparin in the context of cardiac surgery.
Several laboratory tests have been used to diagnose HIT.
These include antigen assays such as ELISA, and functional
assays including the platelet aggregation test, serotonin
release assay,14 the heparin-induced platelet activation
test,15 and an assay using FC that detects platelet
activation.11e13 Although all of these tests are aimed at
detecting antibodies implicated in HIT, none are entirely
satisfactory. ELISA is the most commonly used test for the
detection of HIT antibodies, because it is sensitive, tech-
nically simple, and has commercially available reagents.
However, this assay is not specific for HIT antibodies and
can detect antibodies which do not result in clinical HIT, as
evidenced in our study. Hence, for patients who have pos-
itive ELISA results, further testing with a functional assay
plus clinical assessment by 4Ts is highly recommended to
confirm the HIT diagnosis.7 Although the serotonin release
assay is considered as a gold standard functional assay for
HIT, it is difficult to set up in a general coagulation labo-
ratory and has the risk of radiation exposure.14 As reported
in our previous study, the combination of ELISA and the FC
assay can provide both high sensitivity and specificity for
diagnosis of clinical HIT.16
In this study, 13% of patients were found to have anti-
heparin/PF4 antibodies before surgery, which is suspected
Figure 4 The only patient with positive platelet activation assayed by flow cytometry is depicted here. As compared to no
heparin, the proportion of activated platelets was markedly increased to 48.2% and 37.6% in the presence of 0.1 U/mL and 0.3 U/
mL unfractionated heparin, respectively, and was suppressed to 3.5% in the presence of 100 U/mL unfractionated heparin.
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catheterization, or treatment for ischemic heart disease.
This figure increased to as high as 63% on Day 10 post-
operatively. Table 2 lists the rate of positive heparin/PF4
antibodies, positive platelet activation tested by functional
assays, and the corresponding rates of clinical HIT as re-
ported in six prospective studies in the literature.5,17e21 We
had a higher proportion of positive antibodies as compared
with those in other series, which could be attributed to the
type of ELISA assay used in the present study, which
detected IgM and IgA, in addition to IgG antibodies. In
contrast, the rate of positive platelet activation assay was
1.8% in our study, which is similar to 0.5w3.0% reported in
the literature. No clinical case of HIT was identified in this
study as compared to 0.5w3.2% incidence of clinical HIT
reported in the literature. This may be due to the short
duration of heparin use in cardiopulmonary bypass surgery
and the lack of subsequent use in the intensive care unit for
DVT/PE prophylaxis after surgery.
Thromboembolic diseases such as DVT/PE are not as
prevalent in Taiwan as in Western countries9 and Asianancestry populations carry a lower incidence of venous
thromboembolism (VTE) risk in comparison with African,
European, and Hispanic populations.22 However, the true
incidence of VTE, including HIT, may be underestimated or
underdiagnosed in Taiwan because of low clinical suspicion
and awareness. Recently, in a Japanese prospective
multicenter study on HIT incidence in 172 acute ischemic
stroke patients treated with UFH, the definite HIT inci-
dence was 1.7%.23 In another study reported from India, as
high as eight out of 100 (8%) patients undergoing cardiac
surgery were diagnosed as having confirmed HIT by the pre-
test clinical scoring and antibody assay.24 Therefore, we
believe that HIT deserves clinical attention in Asian and
Taiwanese populations, and more clinical and epidemio-
logical studies are needed to get a better understanding of
this disease in Asian countries.
The platelet count change seen in our cohort of pa-
tients, as depicted in Figs. 1 and 2, is known to be the
typical pattern for patients who undergo cardiopulmonary
bypass surgery, or any other major surgical intervention for
that matter. The platelet count usually falls rapidly after
Table 2 Comparison of frequency of preoperative and postoperative heparin-induced thrombocytopenia (HIT) antibody and
functional assays and clinical HIT in the literature.
Authors Published
year
No. of
patients
Cardiac surgery Positive HIT
antibody assay (%)
Positive HIT
functional
assay (%)
Clinical
HIT (%)
Pre-OP Post-OP Pre-OP Post-OP
Visentin et al17 1996 51 CABG, valve replacement 22 72 None None 0
Bauer et al18 1997 111 Cardiopulmonary bypass 19 51 5a 13a 0
Pouplard et al19 1999 328 CABG, valve replacement
or repair
0.9 25.3 None 2.4a 1.8
Everett et al5 2007 299 CABG, valve replacement
or repair
4.3 22.4 None none 0.7
Kress et al20 2007 1114 CABG, valve surgery 5.4 7.9 None 3.0b 3.2
Selleng et al21 2010 591 CABG, valve surgery, both 21.7 None 1.0c 0.5c 0.5
This study 2012 54 CABG, valve surgery, others 13 63 0 1.8d 0
CABGZ coronary artery bypass graft; HITZ heparin-induced thrombocytopenia; OPZ operation.
a Serotonin release assay.
b Heparin antibody aggregation assay.
c Heparin-induced platelet activation assay.
d Flow cytometry assay.
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operative day, followed by a rise and a return back to the
normal range and even a brief rebound above the normal
range around 1 week later.25 We further explored and
compared the series of platelet count changes in patients
with and without anti-heparin/PF4 antibodies after cardiac
surgery. There were higher platelet counts in patients with
anti-heparin/PF4 antibodies as compared to those in pa-
tients without antibodies at each time point from before
surgery, to Day 10 after surgery, but no statistical differ-
ence was noted. Therefore, it appears that the emergent
anti-heparin/PF4 antibodies during cardiac surgery did not
have a significant effect on platelet consumption or
destruction.
In conclusion, our study demonstrates that around 70%
patients developed anti-heparin/PF4 antibodies in the
context of cardiopulmonary bypass surgery and about 2%
patients had a positive functional assay for platelet acti-
vation. There was no clinical HIT, which may be attributed
to short heparin exposure. We did not use any pharmaco-
logic thromboprophylaxis, including heparin, in the post-
operative setting. These figures are similar to those
reported in Western studies and in general, the rate of
clinical events appears to be very low, despite the high rate
of antibody detection in this subset of patients. To the best
of our knowledge, this is the first study to explore HIT
incidence in the setting of cardiopulmonary bypass surgery
in the Taiwanese population.Acknowledgments
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